Green card applicants are likely to face fee hikes under proposed changes : NPR

Green card applicants are likely to face fee hikes under proposed changes : NPR

U.S. Citizenship and Immigration Services relies nearly entirely on fees to operate.

John Moore/Getty Images


hide caption

toggle caption

John Moore/Getty Images


U.S. Citizenship and Immigration Services relies nearly entirely on fees to operate.

John Moore/Getty Images

After two decades of waiting, Patricia Ramirez of New Mexico was filled with joy when she finally became eligible for a green card a few months ago. To Ramirez, who came to the U.S. undocumented, becoming a lawful permanent resident would give her more security living in the U.S., allow her to visit her family in Mexico, and put her one step closer to becoming a U.S. citizen.

Now, the main obstacle getting in her way is the cost of applications. Ramirez, a house cleaner, has been saving for months to afford the $2,225 in fees for a green card and other forms. Under a new federal proposal, her paperwork may become even more expensive.

“It’s already been a very difficult process, difficult to get information, difficult to save money,” Ramirez told NPR. “I’m so worried and stressed about this and what sacrifices I’ll have to make to afford this.”

U.S. Citizenship and Immigration Services, the federal agency that oversees legal immigration, is planning to raise costs for an array of applications including ones required for citizenship naturalization, to obtain a green card, or to legally work in the U.S. as a noncitizen.

The increases vary, but many immigration attorneys are concerned that the fee hikes could place an undue burden on low-income immigrants — particularly those seeking lawful permanent residency, commonly known as a green card, which allows immigrants long-term stay in the U.S. It is also an important step to become eligible for citizenship.

Under the proposal, Ramirez’s applications will cost $1,500 more than before, according to legal representative Shalini Thomas, who represents Ramirez through the New Mexico Immigrant Law Center.

She added that Ramirez is not the only one who finds the immigration applications unaffordable.

“I’ve had plenty of clients come in and I say, ‘We believe you’re eligible, here is everything that you need, including the fees,’ and I just never hear from them again because I know they can’t save up,” she told NPR. “These changes do not make that better.”

The new costs have not been finalized. USCIS is currently holding a public comment period until March 6.

The federal agency says it needs the increased fees to deal with backlogs and a budget crunch

USCIS primarily relies on fees to operate — which proved to be an issue during the pandemic.

As fewer people applied for immigration benefits, the federal agency’s revenue plummeted, leading to widespread furloughs and a backlog in immigration cases.

To fully recover, the federal agency said it needs to raise application fees, adding that the proposed prices are expected to generate $1.9 billion more per year than current application costs.

“This is the amount necessary to match agency capacity with projected workloads, so that backlogs do not accumulate in the future,” USCIS wrote in its proposal released in early January.

The federal agency generally updates its fee schedule every few years, the last time being 2016. During the Trump administration, there was an attempt to raise costs dramatically, as well make it harder for poor immigrants to qualify for fee waivers, but federal judges eventually blocked those changes.

Karen Sullivan, the director of advocacy at Catholic Legal Immigration Network, Inc., said she wants to see USCIS fully funded, fully staffed and operating efficiently, but questions whether low-income immigrants should have to bear that responsibility.

“All of us should want migrant communities to have access to the benefits that they qualify for,” Sullivan told NPR. “So, I think that Congress should take notice, as far as appropriations go, in helping USCIS with additional funding.”

In fiscal year 2022, the federal agency did receive $275 million from Congress to reduce the current backlog. USCIS expects to continue needing congressional support to fully eliminate it.

The proposed fee changes are a means to allow USCIS to keep up with incoming inventories and avoid future backlogs, the agency said.

A family of four would pay up to $7,460 for green cards and work permits

Under the proposal, applying for a green card with biometrics, or biological measurements, will go up from $1,225 to $1,540. Biometrics — which include fingerprints, a photo and signature — are often required for green cards and other forms.

Although people are currently allowed to apply for a green card and work permit together, the proposed rule will unbundle the forms — which would, in turn, raise costs.

Applications to apply for citizenship may go up by $120; visas for religious workers may increase by $555; and petitions to remove conditions on residence with biometrics, which can allow spouses of green card holders to transition to lawful permanent residents, would increase by $515.

Those fees can especially add up for families filing together.

According to Kathy Klos, an attorney with the Immigrant Law Center of Minnesota, a family of four applying for green cards and two work permits would currently pay $3,950 in fees if filing on paper. That price would go up to $7,460 if they file on paper, and $7,270 if they file online.

“From under $4,000 to almost $7,500 is ridiculous,” Klos told NPR.

The hefty price tag is only one of the hoops to jump through in order to gain legal status in the U.S. Forms can be complicated, processing times can be long and appointments for biometrics or interviews can be a serious inconvenience to students or working adults.

“For people who are born here and never had to deal with the immigration system, they don’t have a great understanding of how difficult it really is,” Klos said.

Fee waivers only help to some extent

USCIS does offer fee waivers to some low-income immigrants and fee exemptions for humanitarian reasons, such as for refugees, asylum-seekers and domestic violence victims.

Generally, households that make less than 150{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8} of the federal poverty line are eligible for discounted applications to a number of immigration benefits. That could include a single adult who makes less than $21,000 per year or a family of four that earns $45,000.

USCIS expects that more than a million applicants — about an eighth of the total — will benefit from fee exemptions or fee waivers each year. But some say the process to apply for one can be long and difficult.

“The fee waivers are not automatic, they add more time to your case,” Daniel Santiago, an attorney with Mabel Center for Immigrant Justice in Boston, told NPR. “And our clients are desperate to get the paperwork done.”

Under the proposed changes, some applications filed online will be cheaper than on paper. USCIS says online applications are easier and cheaper to process than paper ones. But some immigration attorneys find that unfair.

“To offer a discount if you’re filing online helps the most privileged of immigrants, but truly doesn’t help the most marginalized,” said Thomas of the New Mexico Immigrant Law Center.

Thomas said her client, Ramirez, is ineligible for a fee waiver because she is applying for a green card through a family member.

Ramirez has been waiting for an opportunity to become green card eligible for 22 years. Although she’s close to filing the paperwork, Ramirez has a sense that the process has just begun.

“It took me months to pay the current costs. If they go up, I might have to look for another job or get a loan,” she said. “Right now, my plan is to get my application done as soon as possible.”

Drug Price Hikes Already Found in 2023

Drug Price Hikes Already Found in 2023

The median wholesale acquisition cost (WAC) for brand name medicine jumped 5{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8} so significantly in January, and pharma manufacturers have lifted rates on about 450 drugs, in accordance to early data from 46brooklyn Study.

“It is certainly too early to make any wide statements about how 2023 compares with prior several years, as there is just so a lot additional activity that we expect to see just before the conclude of the thirty day period,” Antonio Ciaccia, chief government officer of 46brooklyn, informed Formulary Check out. The 450 cost increases so far in January account for all around a quarter of the overall selection of will increase that Ciaccia expects to see during 2023.

So considerably, on the other hand, overall model drug charges have amplified at a slower level than past year. The weighted general regular WAC selling price increase for all prescription drugs primarily based on Medicaid utilization so much in 2023 is only 1.3{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8}, as opposed with a 5.1{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8} improve in 2022.

In 2022, the median cost improve was 4.9{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8} and about 1,400 drugs had a price tag hike, in accordance to 46brooklyn, nonprofit drug pricing study and education and learning organization begun by the founders of 3 Axis Advisors.

According to 46brooklyn, the largest checklist selling price share increase this month was 26.8{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8} for GE Healthcare’s Omnipaque (iohexol) solution, an oral contrast medium. The most important drop was a 70.2{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8} drop in the list selling price of Amneal’s Lyvispah (baclofen), which is applied to take care of muscle mass stiffness and agony in men and women with multiple sclerosis.

“While it’s hard to pinpoint precise motives for these types of swings, we know that Omnipaque has had a range of provide problems about the earlier calendar year,” Ciaccia explained. “In the experience of greater need amid a extended interval of shortages, it does not surprise me that prices go up in an effort and hard work to fill the void.”

Even though it’s not the major selling price boost, the 5.9{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8} list selling price hike on Gilead’s HIV therapy Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) could have the major effects this 12 months — if the rebates and special discounts available by Gilead don’t keep tempo with the list price tag raises, Ciaccia explained. “A hugely utilised drug like Biktarvy experienced extra than $500 million in gross Medicaid expend in 2022 and much more than $1.7 billion in gross Medicare expend in 2020,” he explained.

The other will increase on significant remedies so considerably include a 6{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8} enhance on Pfizer’s Xeljanz (tofacitinib) for rheumatoid arthritis and other autoimmune ailments, and a 7.9{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8} hike on the company’s Ibrance (palbociclib) and Xalkori (crizotinib) to address most cancers.

In addition, Bristol Myers Squibb’s Auto T-cell therapies Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel) — by now priced large in comparison with other prescription drugs — equally experienced a rate hike of 9{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8} this thirty day period. The price tag increase, however, is the initially considering the fact that launch in the 1st quarter of 2021 for each therapies, “bringing them to record prices comparable with other out there Motor vehicle-T therapies in the market place,” a BMS spokesperson informed Formulary Observe.

“There were a number of driving aspects in this determination, together with the ongoing clinical financial investment, the price of these progressive therapies, the level of inflation, and the refined, individualized nature of the Car T manufacturing course of action,” the spokesperson said.

Throughout the company’s portfolio, BMS expects U.S. net selling prices — which mirror special discounts, rebates, and other value concessions — to remain mostly flat in 2023, the spokesperson said. “Any list price will increase utilize to medicines with ongoing medical investigation and replicate our ongoing initiatives to responsibly value our medications while balancing financial aspects, including inflation and investment decision in new innovation.”

For the last 5 years, BMS has not amplified listing price ranges by far more than 6{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8} every year across its portfolio of medicines with ongoing clinical exploration, with the exception of its CART portfolio, the spokesperson famous. “The complexity of delivering Motor vehicle T-cell therapies is contrary to any other classic biologic or small molecule drugs, using a patient’s individual cells to get started a remarkably sophisticated and individualized manufacturing procedure. Generating a individualized remedy for each individual individual has been incrementally impacted by inflation and other direct and indirect expenses.”

A Pfizer spokesperson said the firm has modified the regular checklist selling prices of all of its medicines and vaccines in 2023 about 3.6{c024931d10daf6b71b41321fa9ba9cd89123fb34a4039ac9f079a256e3c1e6e8}, which is below total inflation. “The modest increase is important to assist investments that allow for us to carry on to discover and provide new medicines as properly as handle elevated expenses throughout our business,” the spokesperson explained.

“For the past four decades, our web charges — the price ranges we in fact get for our prescription drugs — have fallen because of to better rebates and special discounts compensated to insurance policies firms and pharmacy gain supervisors,” the Pfizer spokesperson reported. “Any maximize in individual expenses is probably the final result of greater expense-sharing, by co-insurance policies or deductibles, or greater use. Pfizer is dedicated to increasing by way of expanded use of our medications (desire), not value boosts.”

Ciaccia cautions that WAC details does not inform the total pricing story. “The listing selling prices we’re examining are definitely the surface layer of drug pricing, and even though undoubtedly vital, there is so considerably much more to our exposure to the charges of medicines,” he observed. “The ambiguity of the real expenses of medications is what allows the full drug distribution channel to harvest hidden markups on prescription drug claims at the expense of prepare sponsors, taxpayers, and patients. This opacity additional obfuscates our means to ascertain the real worth a medicine gives. The lack of ability to objectively determine what a truthful rate should really be for the products and solutions and providers supplied by drug channel individuals hinders the potential for real marketplace forces to stress margins and endorse high quality and performance as we search for to equilibrium drug accessibility with affordability.”

This write-up was originally published by our sister model, Formulary Observe.